|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
RGD |
"[Exploration of the theory of ""Fei and Dachang being interior-exteriorly related"" from observing changes of inflammatory cytokines and oxygen free radicals in the lung tissue of ulcerative colitis rats]."
|
24812904 |
2014 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Aims:</b> To evaluate the cost differences between a treatment strategy including tofacitinib (TOFA) vs treatment strategies including adalimumab (ADA), golimumab (GOL), infliximab (IFX), and vedolizumab (VEDO) among all patients with moderate-to-severe ulcerative colitis (UC) (further stratified by patients naïve/exposed to tumor necrosis factor inhibitors [TNFis]).
|
31012362 |
2019 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i>, we adopted the bone marrow-derived macrophages (BMDMs) as well as BMDMs co-cultured with Caco2 cells to verify the underlying mechanisms and effects of JPQC on UC under TNF-α stimulation.
|
31210713 |
2019 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
119 healthy, unrelated controls, 95 patients with Crohn's disease and 93 patients with ulcerative colitis were genotyped for the (G to A) -308 TNF-alpha promoter polymorphism on chromosome 6, the codon 497 EGFR polymorphism on chromosome 7 and the TaqI polymorphism of the VDR gene on chromosome 12.
|
12428072 |
2002 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
|
19286392 |
2009 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Tumor necrosis factor (TNF) superfamily gene-15 (SF15) polymorphisms were associated with CD (OR 2.68; 95% CI 1.86-3.86), while TNF-308 polymorphisms (OR 1.82; 95% CI 1.15-2.9), cytotoxic T lymphocyte antigen (CTLA)-4 (OR 2.75; 95% CI 1.22-6.22) and MICA allele (OR 2.41; 95% CI 1.89-3.07) were associated with ulcerative colitis in Asians.
|
21887729 |
2012 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Tumour necrosis factor-alpha (TNF-α) (-308G/A) is associated with UC onset, suggesting that the presence of -308A allele could confer a relative risk of 3.62 more to develop UC in general population.
|
27528546 |
2016 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor α inhibitors dramatically changed the management of moderate-to-severe phenotypes of ulcerative colitis.
|
27960557 |
2017 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
TNFα has a well-established role in inflammatory bowel disease that affects the gastrointestinal tract and is usually manifested as Crohn's disease or ulcerative colitis.
|
28039805 |
2017 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (AS), psoriasis (Ps) and/or psoriatic arthritis (PsA) and may be administered off-label to treat disseminated granuloma annulare, systemic lupus erythematosus and systemic sclerosis.
|
28837372 |
2018 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TNFα was upregulated in intestinal biopsies from active Crohn`s disease [CD] vs controls [36.2 vs 12.1, p < 0.001], but not ulcerative colitis [UC: 17.9].
|
29182760 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)‑α is a central mediator of intestinal inflammation in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease.
|
29286110 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
A 64-year-old female patient with ulcerative colitis (UC) refractory to tumor necrosis factor inhibitors was treated with VDZ.
|
28655067 |
2017 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A cohort of 103 IBD patients (80 CD, 23 UC) were genotyped and serum level of both anti-TNFs (infliximab or adalimumab) and ADA against them were measured.
|
29333082 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
A cohort of 149 moderately to severely active UC and CD patients who failed or showed intolerance to at least two TNF antagonists participated in a medical need program and received vedolizumab in 37 Belgian centers (April-September 2015).
|
29774158 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
A formal interaction test showed that TNF-857 is associated equally with ulcerative colitis and Crohn's disease.
|
16534418 |
2006 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
A multinational chart review in Europe and Canada was conducted among IBD patients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) who initiated anti-TNF therapy between 2009 and 2013.
|
28826571 |
2017 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
A rat UC model was induced with trinitro-benzene-sulfonic acid (TNBS), concentrations of the cytokines IL-1α, IL-6, IL-8, IL-1β, and TNF-α were significantly up-regulated and the concentrations of IL-4, IL-10, and IL-13 were significantly down-regulated compared with the control group (P < 0.05).
|
31102937 |
2019 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Aberrant activation of the immune response to resident microflora contributes to overproduction of TNF-α in the mucosal tissue of the gastrointestinal tract; a hallmark of UC.
|
30615542 |
2019 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Adalimumab is a recombinant monoclonal antibody to tumor necrosis factor alpha (TNFα) used in the treatment of inflammatory and autoimmune conditions, including ulcerative colitis (UC).
|
30648028 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors.
|
29625907 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
All-Trans Retinoic Acid Modulates TLR4/NF-<i>κ</i>B Signaling Pathway Targeting TNF-<i>α</i> and Nitric Oxide Synthase 2 Expression in Colonic Mucosa during Ulcerative Colitis and Colitis Associated Cancer.
|
28408791 |
2017 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Also HASG was found to reduce the levels of TNF-α and IL-6, thereby suppressing their inflammatory response in UC.
|
29530609 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Also, sensitivity analysis suggested a slightly reduced time from diagnosis to first tumor necrosis factor-α inhibitor treatment among familial CD and UC cases as compared with sporadic cases.
|
26288000 |
2015 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Altered expression of innate immunity genes in different intestinal sites of children with ulcerative colitis.
|
20452301 |
2010 |